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SCIENTIFIC OPINION 
Scientific Opinion on Flavouring Group Evaluation 82, Revision 1 
(FGE.82Rev1): Consideration of Epoxides evaluated by the JECFA 
 (65
th meeting)
1 
EFSA Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
(CEF)
2, 3 
European Food Safety Authority (EFSA), Parma, Italy 
ABSTRACT  
The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids of the European Food Safety 
Authority was requested to consider evaluations of flavouring substances assessed since 2000 by the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA), and to decide whether further evaluation is 
necessary, as laid down in Commission Regulation (EC) No 1565/2000. The present consideration concerns a 
group of five epoxides evaluated by the JECFA at the 65
th meeting in 2005. This revision is made due to 
inclusion of one additional substance, beta-ionone epoxide [FL-no: 07.170], cleared for genotoxicity concern and 
due to additional toxicity data have become available for beta-caryophyllene epoxide [FL-no: 16.043]. Since 
publication of FGE.82 one substance epoxy oxophorone [FL-no: 16.051] is no longer supported for use as 
flavouring substances in Europe by Industry and will therefore not be considered any further. The substances 
were evaluated through a stepwise approach that integrates information on structure-activity relationships, intake 
from current uses, toxicological threshold of concern, and available data on metabolism and toxicity. For four 
substances [FL-no: 16.015, 16.018, 16.040 and 16.043] the Panel agreed with the JECFA conclusion, “No safety 
concern at estimated levels of intake as flavouring substances” based on the MSDI approach. For one substance 
[FL-no: 07.170] additional toxicity data are required. Besides the safety assessment of these flavouring 
substances, the specifications for the materials of commerce have also been considered and for four substances, 
the information is adequate; but for the substance [FL-no: 07.170] further information on stereoisomerism is 
required. 
© European Food Safety Authority, 2014 
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SUMMARY  
Following a request from the European Commission, the EFSA Panel on Food Contact Materials, 
Enzymes, Flavourings and Processing Aids (CEF Panel) was asked to deliver scientific advice to the 
Commission on the implications for human health of chemically defined flavouring substances used in 
or on foodstuffs in the Member States. In particular, the CEF Panel was requested to consider the Joint 
FAO/WHO Expert Committee on Food Additives (the JECFA) evaluations of flavouring substances 
assessed since 2000, and to decide whether no further evaluation is necessary, as laid down in 
Commission Regulation (EC) No 1565/2000. These flavouring substances are listed in the Register, 
which was adopted by Commission Decision 1999/217/EC and its consecutive amendments. 
In Flavouring Group Evaluation 82, the EFSA considered five epoxides evaluated by the JECFA at its 
65
th meeting. Since publication of FGE.82, one substance [FL-no: 16.051] is no longer supported for 
use as flavouring substance in Europe by Industry and will therefore not be considered any further. 
The present revision is made due to inclusion of one additional substance, beta-ionone epoxide [FL-
no: 07.170], cleared for genotoxicity concern in FGE.210 Revision 1 and due to additional toxicity 
data have become available for beta-caryophyllene epoxide [FL-no: 16.043] requested in previous 
version. 
The Panel concluded that no structurally related substances evaluated by EFSA are available for these 
five epoxides in FGE.82, evaluated in the JECFA flavouring group of epoxides. 
Of the further four substances evaluated by the JECFA in this group one is not in the Register and two 
are α,β-unsaturated aldehydes and ketones. These two will be evaluated together with other α,β -
unsaturated aldehydes and ketones. 
The Panel does not agree with the application of the Procedure for the five epoxides as performed by 
the JECFA. For the five substances [FL-no: 07.170, 16.015, 16.018, 16.040 and 16.043] it cannot be 
concluded that they are metabolised to innocuous substances and therefore their evaluation must 
proceed via the B-side of the Procedure scheme.  
A 90-day study on beta-caryophyllene epoxide [FL-no: 16.043] has become available and a NOAEL 
of 109 mg/kg bw/day to provide adequate margin of safety is derived.  
The Panel considered that four of the five substances [FL-no: 16.043, 16.015, 16.018 and 16.040] 
evaluated through the Procedure via the B-side of the Procedure scheme were of no safety concern at 
the estimated levels of intake based on the MSDI approach. 
The evaluation of beta-ionone epoxide [FL-no: 07.170] cannot be finalised at step B4 of the Procedure 
because a NOAEL from a 90-day study is not available. 
For the three substances [FL-no: 16.015, 16.018 and 16.040], evaluated through the Procedure, use 
levels are needed to calculate the mTAMDIs in order to identify those flavouring substances that need 
more refined exposure assessment and to finalise their evaluation. 
In order to determine whether the conclusion for the five JECFA evaluated substances can be applied 
to the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for four JECFA 
evaluated substances [FL-no: 16.015, 16.018, 16.040 and 16.043]. For one substances [FL-no: 07.170] 
information on stereoisomeric composition is not adequate.  
Thus, for one substance evaluated through the Procedure [FL-no: 07.170] the Panel has reservations 
(data missing on stereoisomerism, need for additional toxicity data).  Flavouring Group Evaluation 82 Revision 1
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For the remaining substances [FL-no: 16.015, 16.018, 16.040 and 16.043] the Panel agrees with the 
JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances based on 
the MSDI approach. Flavouring Group Evaluation 82 Revision 1
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BACKGROUND AS PROVIDED BY THE EUROPEAN COMMISSION 
The use of flavourings is regulated under Regulation (EC) No 1334/2008 of the European Parliament 
and Council of 16 December 2008
4 on flavourings and certain food ingredients with flavouring 
properties for use in and on foods. On the basis of Article 9(a) of this Regulation, an evaluation and 
approval are required for flavouring substances. 
The Union list of flavourings and source materials was established by Commission Implementing 
Regulation (EC) No 872/2012
5. The list contains flavouring substances for which the scientific 
evaluation should be completed in accordance with Commission Regulation (EC) No 1565/2000
6. 
EFSA has considered the Joint FAO/WHO Expert Committee on Food Additives (the JECFA) 
evaluation of the flavouring substance beta-caryophyllene epoxide [FL-no: 16.043] in the flavouring 
group evaluation 82 (FGE.82). The opinion was adopted on 1 April 2008. 
EFSA concluded in its opinion that for beta- caryophyllene epoxide or for structurally related 
substances a No Observed Adverse Effect Level (NOAEL) could not be derived. Accordingly, 
additional toxicity data are required for this substance.  
The requested information on the beta-caryophyllene epoxide has now been submitted by the 
European Flavour Association. The Commission asks EFSA to evaluate this new information and 
depending on the outcome proceed to full evaluation of the flavouring substance. 
TERMS OF REFERENCE AS PROVIDED BY THE EUROPEAN COMMISSION 
The European Commission requests the European Food Safety Authority to carry out a safety 
assessment on the flavouring substances, beta-ionone epoxide [FL-no: 07.170] and beta-caryophyllene 
epoxide [FL-no: 16.043] in accordance with Commission Regulation (EC) No 1565/2000. 
INTERPRETATION OF THE TERMS OF REFERENCE  
As additional genotoxicity data have been submitted for beta-ionone epoxide [FL-no: 07.170], the 
European Commission request EFSA to carry out a safety assessment in accordance with Commission 
Regulation (EC) No 1565/2000. 
Beta-ionone epoxide [FL-no: 07.170] was first allocated to FGE.210Rev1 for evaluation with respect 
to genotoxicity. Based on the new genotoxicity data submitted, the Panel concluded that [FL-no: 
07.170] does not give rise to concern with respect to genotoxicity and can accordingly now be 
evaluated through the Procedure in FGE.82Rev1. 
                                                      
4   Regulation (EC) No 1334/2008 of the European Parliament and of the Council of 16 December 2008 on flavourings and 
certain food ingredients with flavouring properties for use in and on foods and amending Council Regulation (EEC) No 
1601/91, Regulations (EC) No 2232/96 and (EC) No 110/2008 and Directive 2000/13/EC. OJ L 354, 31.12.2008, p. 34-50. 
5   Commission implementing Regulation (EU) No 872/2012 of 1 October 2012 adopting the list of flavouring substances 
provided for by Regulation (EC) No 2232/96 of the European Parliament and of the Council, introducing it in Annex I to 
Regulation (EC) No 1334/2008 of the European Parliament and of the Council and repealing Commission Regulation (EC) 
No 1565/2000 and Commission Decision 1999/217/EC. OJ L 267, 2.10.2012, p, 1-161. 
6   Commission Regulation No 1565/2000 of 18 July 2000 laying down the measures necessary for the adoption of an 
evaluation programme in application of Regulation (EC) No 2232/96. OJ L 180, 19.7.2000, p. 8-16. Flavouring Group Evaluation 82 Revision 1
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ASSESSMENT 
The approach used by EFSA for safety evaluation of flavouring substances is referred to in 
Commission Regulation (EC) No 1565/2000, hereafter named the “EFSA Procedure”. This Procedure 
is based on the opinion of the Scientific Committee on Food (SCF, 1999), which has been derived 
from the evaluation procedure developed by the Joint FAO/WHO Expert Committee on Food 
Additives (JECFA, 1995; JECFA, 1996; JECFA, 1997; JECFA, 1999), hereafter named the “JECFA 
Procedure”. The Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids (the 
Panel) compares the JECFA evaluation of structurally related substances with the result of a 
corresponding EFSA evaluation, focussing on specifications, intake estimations and toxicity data, 
especially genotoxicity data. The evaluations by EFSA will conclude whether the flavouring 
substances are of no safety concern at their estimated levels of intake, whether additional data are 
required or whether certain substances should not be evaluated through the EFSA Procedure. 
The following issues are of special importance. 
Intake 
In its evaluation, the Panel as a default uses the Maximised Survey-derived Daily Intake (MSDI) 
approach to estimate the per capita intakes of the flavouring substances in Europe.  
In its evaluation, the JECFA includes intake estimates based on the MSDI approach derived from both 
European and USA production figures. The highest of the two MSDI figures is used in the evaluation 
by the JECFA. It is noted that in several cases, only the MSDI figures from the USA were available, 
meaning that certain flavouring substances have been evaluated by the JECFA only on the basis of 
these figures. For Register substances for which this is the case the Panel will need EU production 
figures in order to finalise the evaluation. 
When the Panel examined the information provided by the European Flavour Industry on the use 
levels in various foods, it appeared obvious that the MSDI approach in a number of cases would 
grossly underestimate the intake by regular consumers of products flavoured at the use level reported 
by the Industry, especially in those cases where the annual production values were reported to be 
small. In consequence, the Panel had reservations about the data on use and use levels provided and 
the intake estimates obtained by the MSDI approach. It is noted that the JECFA, at its 65
th meeting 
considered ”how to improve the identification and assessment of flavouring agents, for which the 
MSDI estimates may be substantially lower than the dietary exposures that would be estimated from 
the anticipated average use levels in foods” (JECFA, 2006a). 
In the absence of more accurate information that would enable the Panel to make a more realistic 
estimate of the intakes of the flavouring substances, the Panel has decided also to perform an estimate 
of the daily intakes per person using a modified Theoretical Added Maximum Daily Intake 
(mTAMDI) approach based on the normal use levels reported by Industry. 
As information on use levels for the flavouring substances has not been requested by the JECFA or 
has not otherwise been provided to the Panel, it is not possible to estimate the daily intakes using the 
mTAMDI approach for the substances evaluated by the JECFA. The Panel will need information on 
use levels in order to finalise the evaluation. 
Threshold of 1.5 Microgram/Person/Day (Step B5) Used by the JECFA 
The JECFA uses the threshold of concern of 1.5 microgram (µg)/person/day as part of the evaluation 
procedure: 
“The Committee noted that this value was based on a risk analysis of known carcinogens which 
involved several conservative assumptions. The use of this value was supported by additional 
information on developmental toxicity, neurotoxicity and immunotoxicity. In the judgement of the Flavouring Group Evaluation 82 Revision 1
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Committee, flavouring substances for which insufficient data are available for them to be evaluated 
using earlier steps in the Procedure, but for which the intake would not exceed 1.5 µg per person per 
day would not be expected to present a safety concern. The Committee recommended that the 
Procedure for the Safety Evaluation of Flavouring Agents used at the forty-sixth meeting be amended 
to include the last step on the right-hand side of the original procedure (“Do the condition of use result 
in an intake greater than 1.5 µg per day?”)” (JECFA, 1999).  
In line with the Opinion expressed by the Scientific Committee on Food (SCF, 1999), the Panel does 
not make use of this threshold of 1.5 µg per person per day. 
Genotoxicity 
As reflected in the Opinion of SCF (SCF, 1999), the Panel has in its evaluation focussed on a possible 
genotoxic potential of the flavouring substances or of structurally related substances. Generally, 
substances for which the Panel has concluded that there is an indication of genotoxic potential in vitro, 
will not be evaluated using the EFSA Procedure until further genotoxicity data are provided. 
Substances for which a genotoxic potential in vivo has been concluded, will not be evaluated through 
the Procedure. 
Specifications 
Regarding specifications, the evaluation by the Panel could lead to a different opinion than that of 
JECFA, since the Panel requests information on e.g. isomerism. 
Structural Relationship  
In the consideration of the JECFA evaluated substances, the Panel will examine the structural 
relationship and metabolism features of the substances within the flavouring group and compare this 
with the corresponding FGE. 
1.  History of the Evaluation of the Substances in the Present FGE  
In FGE.82, which contains a group of five epoxides, the Panel concluded that epoxy oxophorone [FL-
no: 16.051] should not be evaluated through the Procedure, due to concern with respect to 
genotoxicity. For beta-caryophyllene epoxide [FL-no: 16.043] a NOAEL could not be derived for the 
substance or for structurally related substances. Accordingly, additional toxicity data were required for 
this substance. 
Industry has informed that the substance epoxy oxophorone [FL-no: 16.051] is no longer supported for 
use as flavouring substances in Europe (EFFA, 2009) and the substance will therefore not be 
considered any further. 
FGE  Opinion adopted  Link  No. of substances 
FGE.82 1  April  2008  http://www.efsa.europa.eu/en/efsajournal/pub/917.htm 5 
FGE.82Rev1     5 
 
The present revision of FGE.82, FGE.82Rev1, includes the consideration of one additional substance, 
beta-ionone epoxide [FL-no: 07.170]. This substance is an α,β-unsaturated epoxide and was originally 
allocated to and evaluated in FGE.210Rev1 (EFSA CEF Panel, 2014) in which it was considered not 
to be of concern with respect to genotoxicity. 
Additional toxicity data, a 14-day range finding study and a 90-day dietary study, have now been 
provided for beta-caryophyllene epoxide [FL-no: 16.043] (Bauter, 2012; Bauter, 2013). Flavouring Group Evaluation 82 Revision 1
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New information from Industry on missing stereoisomeric composition for [FL-no: 16.015, 16.018 
and 16.040] is also included in the present revision (EFFA, 2013). 
2.  Presentation of the Substances in the JECFA Flavouring Group 
2.1.  Description 
2.1.1.  JECFA Status 
The JECFA has at its 65
th meeting in 2005 evaluated a group of nine flavouring substances consisting 
of epoxides. 
2.1.2.  EFSA Considerations 
One of these is not in the Register, trans-carvone-5,6-oxide (JECFA-no: 1572). Three are α,β -
unsaturated aldehydes or ketones [FL-no: 07.170, 16.044 and 16.071] and will be evaluated together 
with other α,β -unsaturated aldehydes and ketones. The α,β-unsaturated epoxide, beta-ionone epoxide 
[FL-no: 07.170] was evaluated in FGE.210Rev1 (EFSA CEF Panel, 2014) in which the substance was 
considered not to be of concern with respect to genotoxicity. The substance is therefore included in 
this revision of FGE.82. One substance [FL-no: 16.051] is no longer supported for use as flavouring 
substances in Europe and will therefore not be considered any further. Therefore this consideration 
only deals with five substances. The Panel concluded that no corresponding FGE is available. 
2.2.  Isomers 
2.2.1.  Status 
All five substances [FL-no: 07.170, 16.015, 16.018, 16.040 and 16.043] in the group of JECFA 
evaluated epoxides have one or more chiral centres.  
2.2.2.  EFSA Considerations 
Adequate information on isomeric composition is available for four substances. Information is lacking 
about the stereoisomerism for one substance [FL-no: 07.170]. 
2.3.  Specifications 
2.3.1.  Status 
JECFA specifications are available for all five substances (JECFA, 2005) (see Table 2). 
2.3.2.  EFSA Considerations 
Specifications including complete purity criteria and identity are available for four substances [FL-no: 
16.015, 16.018, 16.040 and 16.043]. Information about the stereoisomerism for one substance [FL-no: 
07.170] is lacking. (see Section 2.2.2 and Table 3). 
3.  Intake Estimation 
3.1.  Status 
For all five substances evaluated through the JECFA Procedure production volumes, based on which 
MSDI values can be calculated, are available for the EU (see Table 5). 
3.2.  EFSA Considerations 
For two of the JECFA evaluated substances normal and maximum use levels have been provided by 
the Flavour Industry [FL-no: 07.170 and 16.043] (EFFA, 2004) (see Table 1). Based on these normal Flavouring Group Evaluation 82 Revision 1
 
EFSA Journal 2014;12(6):3708  9
use levels, mTAMDI figures (see Table 2) can be calculated. For definition of normal and maximum 
use levels and description of the method for calculation of mTAMDI consult Annex II in e.g. (EFSA, 
2004).Flavouring Group Evaluation 82 Revision 1 
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Table 1:   Table B.1. Normal and Maximum use Levels (mg/kg) available for JECFA evaluated Substances 
FL-no Food  Categories 
Normal use levels (mg/kg) 
Maximum use levels (mg/kg) 
01.0 02.0 03.0 04.1 04.2 05.0 06.0 07.0 08.0 09.0 10.0 11.0 12.0 13.0 14.1 14.2 15.0 16.0 
07.170  3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
16.043 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
16.051 3 
15 
2 
10 
3 
15 
2 
10 
- 
- 
4 
20 
2 
10 
5 
25 
1 
5 
1 
5 
- 
- 
- 
- 
2 
10 
3 
15 
- 
- 
4 
20 
5 
25 
2 
10 
 
 
Table 2:   Estimated intakes based on the MSDI- and the mTAMDI approach 
FL-
no 
EU Register name  MSDI – EU 
(μg/capita/day) 
MSDI – USA 
(μg/capita/day) 
mTAMDI 
(μg/person/day) 
Structural class  Threshold of concern 
(µg/person/day) 
07.17
0 
beta-Ionone epoxide  0.073  0.1  1000  Class III  90 
16.04
0 
Ethyl 2,3-epoxy-3-methyl-3-
p-tolylpropionate 
20 0.009  ND  Class  III  90 
16.04
3 
beta-Caryophyllene epoxide 8  0.1  1000 Class  III  90 
16.05
1 
Epoxy oxophorone  0.012  0.2 1000  Class  III  90 
16.01
5 
Ethyl methylphenylglycidate  205  1840  ND  Class III  90 
16.01
8 
Ethyl 3-phenyl-2,3-
epoxypropionate 
97 96  ND  Class  III  90 
ND: No intake data available 
SUMMARY OF SPECIFICATION DATA Flavouring Group Evaluation 82 Revision 1 
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Table 3:   Specification Summary of the Substances in the JECFA Flavouring Group (JECFA, 2005) 
FL-no 
JECFA
-no 
EU Register name  Structural formula  FEMA no 
CoE no 
CAS no 
Phys.form 
Mol.formula 
Mol.weight 
Solubility 
(a) 
Solubility in 
ethanol 
(b) 
Boiling point, °C 
(c) 
Melting point, °C 
ID test 
Assay minimum 
Refrac. Index 
(d) 
Spec.gravity 
(e) 
EFSA comments /  
Reference for 
specifications 
07.170 
1571 
beta-Ionone epoxide   f 
O
O
 
4144 
11202 
23267-57-4 
Solid 
C13H20O2 
208.30 
Insoluble 
Soluble 
 
48 
NMR MS 
95 % 
n.a. 
n.a. 
 
 
16.015 
1577 
Ethyl 
methylphenylglycidate 
O
O
O  
2444 
6002 
77-83-8 
Liquid 
C12H14O3 
206.24 
Insoluble 
Soluble 
272-275 
 
IR 
98 % 
1.504-1.513 
1.086-1.096 
Mixture of diastereoisomers 
(two cis (15-25 % each) - and 
two trans-forms (25-35 % 
each) around oxirane ring) 
(EFFA, 2013). 
16.018 
1576 
Ethyl 3-phenyl-2,3-
epoxypropionate 
O
O
O  
2454 
11844 
121-39-1 
Liquid 
C11H12O3 
192.21 
Insoluble 
Soluble 
96 (0.7 hPa) 
 
IR 
98 % 
1.516-1.521 
1.120-1.125 
Mixture of diastereoisomers 
(two cis (15-25 % each) - and 
two trans-forms (25-35 % 
each) around oxirane ring) 
(EFFA, 2013). 
16.040 
1578 
Ethyl 2,3-epoxy-3-methyl-
3-p-tolylpropionate 
O
O
O  
3757 
11707 
74367-97-8 
Liquid 
C13H16O3 
220.27 
Insoluble 
Soluble 
123-125 
 
NMR 
96 % 
1.523-1.529 
1.081-1.087 (20°) 
Mixture of diastereoisomers 
(two cis (15-25 % each) - and 
two trans-forms (25-35 % 
each) around oxirane ring) 
(EFFA, 2013). 
16.043 
1575 
beta-Caryophyllene 
epoxide  O
4085 
10500 
1139-30-6 
Solid 
C15H24O 
220.36 
Insoluble 
Soluble 
 
61 
NMR MS 
95 % 
n.a. 
n.a. 
Register name to be changed 
to 1R,4R,6R,10S-beta-
caryophyllene epoxide. 
16.051 
1573 
Epoxy oxophorone 
O
O
O  
 
 
38284-11-6 
Solid 
C9H12O3 
168.19 
Insoluble 
Soluble 
 
157 
NMR MS 
95 % 
n.a. 
n.a. 
No longer supported by 
Industry, DG SANCO, 2012. 
Racemic mixture (Me up & 
epoxy down or Me down and 
epoxy up) configuration of 
epoxyde up or down i.e. 
racemate (EFFA, 2010a). 
(a):  Solubility in water, if not otherwise stated. 
(b):  Solubility in 95 % ethanol, if not otherwise stated. 
(c):  At 1013.25 hPa, if not otherwise stated. 
(d):  At 20°C, if not otherwise stated. 
(e):  At 25°C, if not otherwise stated. 
(f):  Stereoisomeric composition not specified. Flavouring Group Evaluation 82 Revision 1 
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4.  GENOTOXICITY DATA 
4.1.  Genotoxicity Studies – Text Taken
7 from the JECFA (JECFA, 2006b) 
In vitro 
In standard assays for reverse mutation in Salmonella typhimurium, ethyl methylphenylglycidate [FL-
no: 16.015] and caryophyllene oxide (beta-caryophyllene epoxide) [FL-no: 16.043] were consistently 
non-mutagenic in strains TA98, TA100, TA1535, TA1537 and TA1538 at concentrations of up to 
10,000 μg/plate, with and without metabolic activation (S9) (Richold et al., 1979; Voogd et al., 1981; 
Wild et al., 1983; Canter et al., 1986). Ethyl 3-phenylglycidate (ethyl-3-phenyl-2,3- epoxyproprionate) 
[FL-no: 16.018] gave inconsistent results in this test: at ≤ 4,000 µg/plate, it did not induce reverse 
mutations in S. typhimurium TA1535, TA1537 or TA1538 with or without metabolic activation (Wild 
et al., 1983; Tilch and Elias, 1984; Canter et al., 1986); however negative results were reported in 
several studies in TA98 incubated with ethyl 3-phenylglycidate at concentrations ≤ 4,000 µg/plate, 
irrespective of metabolic activation (Wild et al., 1983; Tilch and Elias, 1984; Canter et al., 1986; 
Wagner and Walton, 1999), whereas increased mutagenicity was found in TA98 with metabolic 
activation (≤ 5,000 µg/plate). In the absence of metabolic activation, the frequency of revertants was 
comparable to that of controls (Wagner and Walton, 1999).  
Although Canter et al. (1986) reported negative results in TA100 incubated with ethyl 3-
phenylglycidate at ≤ 2,200 µg/plate with and without metabolic activation, positive results were 
reported with and without metabolic activation in other studies (Voogd et al., 1981; Wild et al., 1983; 
Tilch and Elias, 1984; Wagner and Walton, 1999). In the study of Voogd et al. (1981), positive results 
were found only at the two highest concentrations (1,000 and 2,000 µg/ml), with and without 
metabolic activation. Only a weak mutagenic response was reported by Tilch and Elias (1984) and 
only in the presence of metabolic activation. In an assay in which the mutagenicity of a pepsin and 
pancreatin digest of ethyl 3-phenylglycidate (≤ 10,000 µg/plate), simulating mammalian digestion, 
was investigated in several strains of S. typhimurium including TA100, no increase in the mutagenic 
response was observed (Tilch and Elias, 1984). 
In Escherichia coli PQ37, ethyl 3-phenylglycidate [FL-no: 16.018] was not mutagenic in the SOS 
Chromotest with or without metabolic activation (von der Hude et al., 1990a).  
Ethyl 3-phenylglycidate [FL-no: 16.018] was clastogenic in Chinese hamster ovary (103 µg/mL) and 
V79 cells (480.5 µg/mL) with and without metabolic activation (Tilch and Elias, 1984; von der Hude 
et al., 1991); however, when ethyl 3-phenylglycidate was pre-treated with artificial digestive juices 
conducive to the formation of the corresponding diol and, subsequently, incubated with Chinese 
hamster ovary cells, no sister chromatid exchange was reported at concentrations ≤ 3,280 µg/mL 
(Tilch and Elias, 1984).  
Ethyl methylphenylglycidate [FL-no: 16.015] at ≤ 160 µg/ml induced a significant increase in the 
number of sister chromatid exchanges when tested in the absence of rat liver S9; however, no increase 
in sister chromatid exchange frequency was observed in the presence of metabolic activation (≤ 500 
µg/mL). Similarly, ethyl methylphenylglycidate ≤ 500 µg/ml induced chromosomal aberrations 
without metabolic activation. Although aberrations also occurred in the presence of S9, the results 
were considered equivocal owing to the lack of statistical significance in the Dunnett test (Galloway et 
al., 1987). 
                                                      
7  The text is taken verbatim from the indicated reference source, but text related to substances not included in the present  
   FGE has been removed. Flavouring Group Evaluation 82 Revision 1 
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Figure 1: Structures and absolute configurations of optically active trans- and cis-methyl epoxycinnamate (3-phenyl-2,3-
epoxypropanoate) and the urinary metabolites isolated from rats. (From (Rietveld et al., 1988)) 
 
In order to assess further the potential mutagenicity and genotoxicity of the epoxides, the results of a 
number of assays performed with structurally related glycidic and cycloaliphatic epoxide compounds 
were reviewed. The structurally related glycidic ester, racemic cis-methyl epoxycinnamate (II; see 
Figure 1) at ≤ 15,000 µg/plate was not mutagenic to S. typhimurium strains TA98, TA100, TA1535, 
TA1537 and TA1538 with or without metabolic activation in the plate incorporation test. In contrast, 
racemic trans-methyl epoxycinnamate (I; see Figure 1) at ≤ 15,000 µg/plate was mutagenic in S. 
typhimurium strains TA1535, TA1537, TA1538 and TA100, but not TA 98, without metabolic 
activation. With metabolic activation, no significant increases in mutagenic activity were observed in 
any of the tester strains. When the individual diastereomers of cis- (V and VI; see Figure 1) and trans-
methyl epoxycinnamate (III and VI; see Figure 1) were incubated at 1,500 or 3,000 µg/plate with S. 
typhimurium TA100 in the absence of metabolic activation, the trans isomers showed the greatest 
mutagenicity, compound IV being the most active (IV < III < VI < V) (Rietveld et al., 1988). The 
authors correlated these results with the increased N-alkylating potential of trans isomers discussed 
above. 
The potential genotoxicity of several structurally related aliphatic cyclic epoxides was also 
investigated in the Ames assay and SOS Chromotest. Although cyclopentane oxide and cyclohexane 
oxide were mutagenic in the Ames test, neither was active in the SOS Chromotest. Furthermore, 
cyclooctane oxide, cyclododecane oxide, (-)-2,3-epoxypinane and (+)-limonene oxide gave uniformly 
negative results in both assays (Basler et al., 1989). No other experimental details were provided in 
this abstract.  
A series of cycloaliphatic epoxides was evaluated in the Ames assay with the standard battery of S. 
typhimurium strains (TA98, TA100, TA1535, TA1537 and TA1538) without metabolic activation. 
After incubation with cyclopentane oxide, cyclohexane oxide or norbornane oxide at 15-60 µmol/l, 
significant increases in the number of reverse mutations were observed only in TA100 and TA1535 in 
comparison with controls (Frantz and Sinsheimer, 1981). In another study, cyclohexane oxide also 
gave negative results in the standard Ames plate assay, but a significant increase in the number of 
reverse mutations was observed in S. typhimurium TA100 in a liquid test system (0.33 to 10 mmol/l) 
(Turchi et al., 1981). In a comparison of the potential mutagenicity of cycloalkane epoxides with 
increasingly expanding ring sizes (cyclopentane oxide, cyclohexane oxide, cycloheptane oxide, 
cyclooctane oxide and cyclododecane oxide) in S. typhimurium TA1535 and TA100 (12 µmol/plate), 
statistically significant mutagenic responses were obtained with cyclopentane oxide and cyclohexane 
oxide. Moreover, a slight but statistically significant increase in revertant frequency was observed with 
cycloheptane oxide, although the increase occurred in the presence of marked cytotoxicity. The 
mutation frequency observed with cyclooctane oxide was comparable to the spontaneous background 
levels. No viable colonies were detected following incubation of either S. typhimurium tester strain 
with cyclododecane oxide. Generally, therefore, the genotoxic potential of cycloaliphatic epoxides 
appears to be related inversely to the ring size; however, compounds with increasing ring sizes were Flavouring Group Evaluation 82 Revision 1 
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shown to be increasingly cytotoxic. Consequently, specially constructed base-pair mutagen detector S. 
typhimurium strains (i.e., TA92, TA1950 and TA2410), which have a normal lipopolysaccharide cell-
wall coating as opposed to the more permeable coating of the TA100 and TA1535 strains, were used 
in an attempt to separate the mutagenic response from the confounding toxicity. The ratios of 
mutagenicity to relative toxicity observed after incubation of the normally coated strains with 
cyclohexane oxide, cyclooctane oxide and cyclododecane oxide were comparable to those observed in 
the more permeable strains, indicating that the increase in the mutation frequency was not due to the 
concomitant cytotoxicity (Frantz and Sinsheimer, 1981). 
In eukaryotic V79 Chinese hamster cells, a weak but concentration-dependent increase in the 
occurrence of sister chromatid exchanges were observed in the presence of epoxycyclopentane and 
epoxycyclohexane. In contrast, V79 Chinese hamster cells incubated with epoxycyclooctane, 
epoxycyclododecane or (+)-limonene oxide showed no increase in sister chromatid exchange (von der 
Hude et al., 1991). Significant increases in mutant frequencies were reported when cyclohexane oxide 
(≤ 5 mmol/l) was incubated with V79 Chinese hamster cells. Cyclohexane oxide (10 mmol/l) also 
increased the micronucleus frequency and the number of chromosomal aberrations (bridges and 
lagging chromosomes) in the Chinese hamster cells (Turchi et al., 1981).  
1,2-Epoxyoctane, 1,2-epoxydecane, epoxycyclooctane, epoxycyclododecane, (+)-limonene oxide, α-
pinane oxide and cis-2,3-epoxysuccinic acid did not induce unscheduled DNA synthesis in primary rat 
hepatocytes (von der Hude et al., 1990b). 
In vivo 
The potential of ethyl methylphenylglycidate [FL-no: 16.015] and ethyl 3-phenylglycidate [FL-no: 
16.018] to induce sex-linked recessive lethal mutations in adult Drosophila melanogaster was studied 
in the Basc test. The mutation frequency was significantly increased in flies after 3-days’ exposure to 
2.5 or 10 mmol/l solutions of ethyl 3-phenylglycidate (480 µg/ml) or ethyl methylphenylglycidate 
(2062.4 g/ml), respectively; however, the increases were statistically significant in only one of the 
experiments conducted with each compound and only in the first of three broods tested. Although the 
isolated increase in mutation frequency observed with ethyl 3-phenylglycidate did not affect the 
overall number of sex-linked recessive lethal mutations in brood 1, the total number of mutations in 
brood 1 after exposure to ethyl methylphenylglycidate was significantly greater than in controls. The 
authors concluded that ethyl methylphenylglycidate is only weakly mutagenic in Drosophila (Wild et 
al., 1983).  
The frequencies of micronucleated bone-marrow erythrocytes obtained from groups of four male and 
four female NMRI mice 30 hours after administration of a single intraperitoneal dose of 619, 1237 or 
1,856 mg/kg bw of ethyl methylphenylglycidate [FL-no: 16.015] or 577, 961 or 1,538 mg/kg bw of 
ethyl 3-phenylglycidate [FL-no: 16.018] were comparable to those in the corresponding controls (Wild 
et al., 1983). 
Conclusion on genotoxicity 
The genotoxic potential of glycidate and alicyclic epoxides was studied in several standard assays in 
bacteria and mammalian cells in vitro. In the Ames assay for reverse mutation, both caryophyllene 
oxide [FL-no: 16.043] and ethyl methylphenylglycidate [FL-no: 16.015] gave unequivocally negative 
results with and without metabolic activation in a series of standard S. typhimurium tester strains. 
Ethyl 3-phenylglycidate [FL-no: 16.018] gave positive results only in S. typhimurium strains TA100 
and TA98 and mainly in the presence of metabolic activation; however, a digest of ethyl 3-
phenylglycidate had no mutagenic potential in S. typhimurium TA100 and TA98 with or without 
metabolic activation. Negative results were reported with cis-methyl epoxycinnamate, a structurally 
related glycidic ester, in the standard battery of S. typhimurium tester strains, but trans-methyl 
epoxycinnamate was mutagenic in TA1535, TA1537, TA1538 and TA100, only in the absence of 
metabolic activation. Cyclopentane and cyclohexane oxide induced reverse mutation in S. Flavouring Group Evaluation 82 Revision 1 
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typhimurium strains TA1535 and TA100. Although, cycloaliphatic epoxides of larger ring size were 
generally less mutagenic activity than the smaller-ring epoxides, marked cytotoxicity was seen. 
Uniformly negative results were obtained in the SOS Chromotest in E. coli. Although clastogenic 
activity was reported in mammalian cell lines with most glycidate and alicyclic epoxides, increased 
sister chromatid exchange frequencies were observed with ethyl methylphenylglycidate only in the 
absence of metabolic activation. Likewise, chromosomal aberrations were reported in Chinese hamster 
ovary cells incubated with ethyl methylphenylglycidate or cyclohexane oxide, but the results with 
ethyl methylphenylglycidate were equivocal when S9 activation was incorporated into the assay. No 
unscheduled DNA synthesis was found with a series of epoxyalkanes and alicyclic epoxides.  
In vivo, ethyl methylphenylglycidate had slight potential to induce sex-linked recessive lethal 
mutations in Drosophila, but ethyl 3-phenylglycidate showed no activity. Ethyl 3-phenylglycidate and 
ethyl methylphenylglycidate did not induce micronucleous formation in mice given single 
intraperitoneal doses. 
Epoxides are naturally occurring substances that are also added to food as flavouring agents. The 
principal epoxide used in this way is ethyl methylphenylglycidate. Studies on the metabolism of 
glycidate and alicyclic (including terpene) epoxides indicate that these compounds are readily and 
adequately detoxicated in animals via two pathways, GSH conjugation and hydrolysis in the 
gastrointestinal tract or other tissues, followed by glucuronic acid or sulphate conjugation in the liver. 
Although glycidate and alicyclic epoxides had some genotoxic potential in standard assays in vitro, the 
results of assays for genotoxicity in mammals in vivo were negative. Furthermore, a number of long-
term studies with dietary administration provided no evidences of carcinogenic potential. Several 
long-term studies with repeated doses of ethyl methylphenylglycidate showed no carcinogenicity even 
at intake levels that were orders of magnitude higher than the intake of epoxides added as flavouring 
agents. The NOEL in the 2-year bioassay of ethyl methylphenylglycidate was 35 mg/kg bw per day. 
This intake level is > 1100 times the daily per capita intake (“eaters only”) of 0.031 mg/kg bw per day 
from use of ethyl methylphenylglycidate as a flavouring agent. 
The known pathways of metabolic detoxication, the lack of evidence of carcinogenicity in long-term 
feeding studies and the lack of genotoxic potential in vivo indicate that it is unlikely that epoxides pose 
a significant genotoxic risk to humans under the conditions of their use as flavouring agents. 
For a summary of in vitro / in vivo genotoxicity data considered by the JECFA see Table.4. 
4.2.  Genotoxicity Studies – Text Taken
8 from EFSA FGE.210Rev1 (EFSA CEF 
Panel, 2014) 
Bacterial Reverse Mutation Assay 
beta-Ionone epoxide [FL-no: 07.170] was tested for mutagenicity in an Ames test including four 
strains of S. typhimurium (TA98, TA100, TA1535 and TA1537) at five concentrations (5, 15, 50, 150, 
500 μg/plate) in the absence and in the presence of metabolic activation (S9-mix at two different 
concentrations, 3 and 10 %) (Jones and Wilson, 1988). The study was performed under GLP and 
mainly compliant with OECD Guideline 471 (OECD, 1997), except that only four strains were used. 
Two independent experiments were performed and the top concentration was selected at 500 μg/plate 
based on toxicity in a prior range-finding test. At the concentration tested no significant toxicity was 
observed and no substantial increases in mutation were observed in all strains tested and in presence or 
absence of S9.  
A more recently reported Ames study on beta-ionone-epoxide included four strains of S. typhimurium 
(TA97a, TA98, TA100 and TA1535) plus one strain of E. coli (WP2-uvrA-) (Kringstad, 2005). 
Following a range-finding assay, beta-ionone was tested in three replicates at 501, 1582 and 5000 
                                                      
8  The text is taken verbatim from the indicated reference source, but text related to substances not included in the present 
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μg/plate in the absence of S9-mix metabolic activation and at 158, 501 and 1582 μg/plate in the 
presence of metabolic activation, in a single experiment using the plate incorporation method. The top 
concentration (5000 μg/plate) induced significant toxicity in strain TA97a in the absence of S9-mix 
and also reduced the background lawn in strain TA100 in the presence and absence of S9-mix and 
therefore the study complies with current recommendations for the choice of concentration. There was 
no evidence of mutagenicity. Since there are some deviations from the OECD Guideline 471 (OECD, 
1997) (only three concentrations of chemical were tested, in some cases only two concentrations could 
be analysed due to an excessive level of cytotoxicity and only a single experiment was performed) the 
test is considered of limited validity. 
Mouse lymphoma thymidine kinase gene mutation assay  
An assay for induction of tk  mutations in mouse lymphoma cells (L5178Y T/K +/- 3.7.2c) was 
conducted on beta-ionone-epoxide [FL-no: 07.170] (Flanders, 2006). It included four hours treatment 
in the absence and presence of S9-mix and a 24 hours treatment in the absence of S9-mix. The 
concentrations were selected based on a preliminary toxicity test. The test groups included single 
replicates at 8 concentrations ranging from 200 to 900 μg/ml in the four hours treatment arm and from 
4.1 to 520 μg/ml in the 24 hours treatment arm. The maximum concentration was limited by toxicity. 
The substance did not induce biologically or statistically significant increases in mutant frequency and 
therefore it was considered non-mutagenic in this assay. The study is compliant with OECD Guideline 
476 (OECD, 1997). 
For a summary of in vitro genotoxicity data considered by the EFSA in FGE.210Rev1, see Table 5. 
4.3.  EFSA Considerations 
Data from in vitro tests are available for four substances [FL-no: 07.170, 16.015, 16.018 and 16.043]. 
Data from in vivo tests are available for two substances [FL-no: 16.015 and 16.018].  
In vitro 
The epoxide group and the terminal double bond in beta-caryophyllene epoxide [FL-no: 16.043] 
represent structural alerts for a genotoxic potential. However this substance was tested for bacterial 
gene mutations in a valid Ames test (TA98, TA100, TA1535, TA1537 and TA1538) where negative 
results were reported (Table 4). 
The substance ethyl 3-phenyl-2,3-epoxypropionate [FL-no: 16.018] was positive in bacterial gene 
mutation tests (Ames) in strain TA100 in the majority of the available studies either in the presence of 
S9 or both in the absence and in the presence of S9. The effect was dose-related and occurred only in 
studies in which the concentration range tested reached cytotoxic levels. Negative responses were 
observed in strains TA1535, TA1537, TA1538 and TA98. Furthermore, ethyl 3-phenyl-2,3-
epoxypropionate induced forward mutations in mammalian cells (HGPRT locus test in Chinese 
hamster ovary (CHO) cells) both in the absence and presence of metabolic activation and induced 
sister chromatid exchanges (SCE) in CHO cells in two studies, one of which had only a limited report. 
Ethyl 3-phenyl-2,3-epoxypropionate was negative in an SOS chromotest (Table 4). 
The substance ethyl methylphenylglycidate [FL-no: 16.015] was consistently negative in the available 
bacterial gene mutation studies at up to cytotoxic concentrations. In contrast, ethyl 
methylphenylglycidate induced SCE and chromosomal aberrations in CHO cells in the absence of 
metabolic activation, while in the presence of S9 the observed response was negative for SCE and 
equivocal for chromosomal aberrations (Table 4).  
 In FGE.210Rev1 the concern for genotoxicity for beta-ionone epoxide [FL-no: 07.170] was ruled out  
(Table 5).  
 Flavouring Group Evaluation 82 Revision 1 
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In vivo 
In in vivo studies, ethyl 3-phenyl-2,3-epoxypropionate [FL-no: 16.018] did not induce mutations in 
Drosophila melanogaster, whereas ethyl methylphenylglycidate [FL-no: 16.015] was found weakly 
positive in the same study. For both substances a negative result was reported in a micronucleus test in 
the mouse bone marrow, the validity of which, however, cannot be evaluated.  
The genotoxic potential of ethyl methylphenylglycidate [FL-no: 16.015] indicated by the in vitro 
studies was not substantiated by the in vivo micronucleous studies. Nevertheless, the available 
carcinogenicity study in rats (2 years) (Dunnington et al., 1981) gives no evidence for a carcinogenic 
activity of ethyl methylphenylglycidate. Ethyl methylphenylglycidate is structurally closely related to 
the candidate substances ethyl 3-phenyl-2,3-epoxypropionate [FL-no: 16.018] and ethyl 2,3-epoxy-3-
methyl-3-p-tolylpropionate [FL-no: 16.040]. For the latter, no genotoxicity data are available. It is 
therefore concluded that the structural alert for genotoxicity of the two compounds as well as the 
evidence for a genotoxic potential from the available in vitro studies on ethyl 3-phenyl-2,3-
epoxypropionate are outweighed by the negative findings on ethyl methylphenylglycidate.  
Conclusion on genotoxicity 
Data on the genotoxicity of the flavouring substances in this group are limited and the genotoxicity 
could not be assessed adequately for these substances. For ethyl methylphenylglycidate [FL-no: 
16.015], ethyl 3-phenyl-2,3-epoxypropionate [FL-no: 16.018], ethyl 2,3-epoxy-3-methyl-3-p-
tolylpropionate [FL-no: 16.040], beta-caryophyllene epoxide [FL-no: 16.043] the Panel concluded that 
the available data do not preclude their evaluation through the Procedure. 
The data available for beta-ionone epoxide [FL-no: 07.170]  demonstrated that this substance is not 
genotoxic. 
5.  14-DAY AND 90-DAY STUDY ON BETA-CARYOPHYLLENE EPOXIDE [FL-NO: 16.043] 
A 14-day range-finding dietary study was performed with 5 beta-caryophyllene epoxide [FL-no: 
16.043] (Bauter, 2012). Groups (3/sex/dietary intake level) of male and female Hsd:SD®  rats were 
fed a diet containing 0 (dietary control), 3000, 9000 and 18000 mg/kg diet of beta-caryophyllene 
epoxide daily. These estimated dietary levels correspond to the measured intake of 279, 789 and 1,558 
mg/kg body weight (bw)/day for males and 268, 816 and 1586 mg/kg bw/day for females. Clinical 
observations were recorded daily and body weights and food consumption observations were made on 
days 0, 7 and 14. No mortality was observed throughout the course of the study and the general 
condition of the rats was unremarkable. The body weight gain and gross examination were comparable 
to controls. Based on the conditions of this 14-day study it was suggested that rats of both sexes 
should tolerate beta-caryophyllene epoxide at concentrations up to or greater than 18000 mg/kg diet 
(Bauter, 2012). 
A 90-day dietary study was performed with beta-caryophyllene epoxide [FL-no: 16.043] (Bauter, 
2013). The study was performed according to OECD guideline (TG 408). Four groups of rats 
(10/sex/dietary intake level) of male and female CRL Sprague-Dawley CD®IGS rats were fed a diet 
containing 0 (dietary control), 1,750, 10,500 and 21,000 mg/kg diet of beta-caryophyllene epoxide. 
These estimated dietary levels correspond to the measured daily intake of 0, 109, 672 and 1398 mg/kg 
bw, respectively for males and 0, 137, 800 and 1660 mg/kg bw, respectively for females. 
Clinical observations of toxicity were performed on day 0 and weekly until sacrifice. Animals were 
weighed on day 0 at the start of the study and weekly thereafter. Food consumption and efficiency 
were measured and calculated weekly. Blood chemistry and haematology were performed on blood 
drawn via sublingual bleed during week 12 after overnight fast. Urine was collected during the 15 
hours prior to the blood draw. At termination of the study all survivors were sacrificed and subject to 
full necropsy. The following tissues were weighed wet post dissection: adrenals, brain, epididymides, Flavouring Group Evaluation 82 Revision 1 
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heart, kidneys, liver, ovaries, testes, spleen, thymus, uterus with oviducts. The tissues were preserved 
for future histopathological examination according to TG 408. 
No gross observations were attributed to beta-caryophyllene epoxide in the diet. A concentration-
dependent increase in kidney weights for males reaching significance at the highest intake level 
correlated with microscopic findings both of which are most likely α2u-globulin nephropathy, a 
common condition in the male rat. Fine granular casts and concentration-dependent increase in volume 
were found upon examination of the urine. Nephropathy was indicated by tubular cytoplasmic droplets 
in the kidneys of all test group males. Kidney cells of affected males were reported to have necrotic 
nuclei and increase in eosinophilic cytoplasm. There were also increases in the number and size of 
hyaline droplets present in the kidneys consistent with this spontaneous nephropathy, no such droplets 
were seen in the female group. 
The Panel concluded that because of the specificity of the phenomenon of hyaline droplet in the 
kidneys to male individuals of the here used rat strain, this effect was not considered relevant for 
humans. (Capen et al., 1999, Olson et al., 1990) 
All males and females of the middle and high intake level groups were reported to show hepatocellular 
hypertrophy. Additionally, microscopic findings in the liver and mesenteric lymphnodes were reported 
at the mid and high intake levels for both sexes. Evidence of liver hypertrophy in both male and 
female rats was consistent with an adaptive response to the increased metabolic load resulting from 
exposure to the two highest dietary levels of the test substance. The presence of hepatocyte 
hypertrophy in both sexes, the increases in absolute and relative liver weights at the mid- and highest 
dietary levels, and the absence of any other significant abnormality upon histopathologic examination, 
mutually support the conclusion that the hepatocyte hypertrophy is the result of hepatic enzyme 
induction and is considered an adaptive effect. Erythrocytes were present in the sinuses of the 
mesenteric lymphnodes. Additionally, reduced spleen weights for males at the highest dietary level 
were considered related to general reductions in lymphoid system weights. 
The Panel asserts that under the conditions of this 90-day dietary toxicity study and based on the 
toxicological endpoint of mesenteric lymph node pathology, the no-observed-adverse-effect level 
(NOAEL) for beta-caryophyllene epoxide in the diet is 1750 mg/kg diet for males and females, which 
corresponds to the calculated intake of 109 mg/kg bw/day for males and 137 mg/kg bw/day of beta-
caryophyllene epoxide for females(Bauter, 2013).  
5.1.  EFSA Considerations 
For beta-caryophyllene epoxide [FL-no: 16.043] a NOAEL of 109 mg/kg bw/day has been established 
and this NOAEL will be used to evaluate this substance in the procedure. No NOAEL is available for 
beta-ionone epoxide or for a structurally related substance.  
6.  APPLICATION OF THE PROCEDURE 
6.1.  Application of the Procedure to Aliphatic Amines and Amides Substances by 
the JECFA (JECFA, 2006b) 
According to the JECFA all five substances belong to structural class III using the decision tree 
approach presented by Cramer et al. (Cramer et al., 1978). 
According to the JECFA all five substances can be predicted to be metabolised to innocuous products, 
so they were evaluated by the JECFA along the A-side of the Procedure. 
The JECFA concluded three epoxides [FL-no: 07.170, 16.040 and 16.043] at step A3 in the JECFA 
Procedure, i.e. the substances are expected to be metabolised to innocuous products (step 2) and the 
intakes for the substances are below the threshold for structural class III (step A3). Flavouring Group Evaluation 82 Revision 1 
 
EFSA Journal 2014;12(6):3708  19
The two substances [FL-no: 16.015 and 16.018], for which the intakes are above the threshold, do not 
occur endogenously in humans. Therefore the evaluation proceeded to step A5, where the substances 
were considered of no safety concern at the estimated levels of intake based on a long-term study, in 
which a NOAEL of 35 mg/kg bw/day for ethyl methylphenylglycidate [FL-no: 16.015] provides a 
margin of safety of more than 8000. This NOAEL is more than 17000 times the estimated intake of 
the related substance, ethyl 3-phenylglycidate [FL-no: 16.018]. The JECFA therefore concluded that 
these flavouring substances would not present a safety concern at the estimated daily intakes. 
In conclusion, the JECFA evaluated all five substances to be of no safety concern at the estimated 
levels of intake as flavouring substances based on the MSDI approach. 
The evaluations of the epoxides are summarised in Table 6. 
6.2.  EFSA Considerations 
The Panel does not agree with the application of the Procedure for the epoxides as performed by 
JECFA. The five substances [FL-no: 07.170, 16.015, 16.018, 16.040 and 16.043] should be evaluated 
via the B-side of the Procedure scheme. 
For the epoxides ethyl methylphenylglycidate [FL-no: 16.015] and ethyl 3-phenyl-2,3-
epoxypropionate [FL-no: 16.018] there is substantial evidence of a genotoxic potential from the 
available  in vitro and in vivo studies. However, for ethyl methylphenylglycidate [FL-no: 16.015] 
negative carcinogenicity study is available, which is considered valid by the Panel. Groups of 48 male 
and 48 female rats were given diet containing 0 (control), 0.02, 0.1 or 0.5 % ethyl 
methylphenylglycidate for 2 years. Reduced weight of female rats given 0.5 % ethyl 
methylphenylglycidate in the diet were observed as well as reduced glutamic-oxalacetic transaminase 
levels in serum for both male and females at the highest dose. A NOAEL of 0.1 % ethyl 
methylphenylglycidate in the diet (corresponding to 35 mg/kg bw/day for males and 60 mg/kg bw/day 
for females) was established (Dunnington et al., 1981). A NOAEL of 109 mg/kg bw/day was 
established for beta-caryophyllene epoxide [FL-no: 16.043]. A concern for genotoxicity was ruled out 
for beta-ionone epoxide [FL-no: 07.170]. The Panel finally consider that the negative results from the 
carcinogenicity study overrule the positive in vitro genotoxicity results and the positive sex-linked 
recessive lethal mutation assay for ethyl methylphenylglycidate [FL-no: 16.015] and the structurally 
related substances ethyl 3-phenyl-2,3-epoxypropionate [FL-no: 16.018] and ethyl 2,3-epoxy-3-methyl-
3-p-tolylpropionate [FL-no: 16.040]. 
Accordingly, three substances [FL-no: 16.015, 16.018 and 16.040] as well as beta-caryophyllene 
epoxide [FL-no: 16.043] and beta-ionone epoxide [FL-no: 07.170] can be evaluated via the B-side of 
the Procedure scheme. All five substances are classified into structural class III. Two of the substances 
[FL-no: 16.015 and 16.018] have estimated European daily per capita intakes from use as flavourings 
of 205 and 97 µg/capita/day, which are above the threshold of concern for structural class III, while 
the last three substances [FL-no: 07.170, 16.040 and 16.043] have estimated intakes of 0.073, 20 and 8 
µg/capita/day, respectively, which are below the threshold of concern for structural class III. A 
NOAEL of 35 mg/kg bw/day can be derived from the carcinogenicity study with ethyl 
methylphenylglycidate [FL-no: 16.015] in male rats, which also applies to the structurally related 
substances [FL-no: 16.018 and 16.040]. The combined intake of the three substances is 322 
µg/capita/day. This provides an adequate margin of safety for the substances of approximately 7 x 10
3.  
Additional toxicity data have now become available for beta-caryophyllene epoxide [FL-no: 16.043] 
and based on these new data a NOAEL of 109 mg/kg bw/day could be derived. Based on the MSDI 
for this substance an adequate margin of safety of approximately 8 x 10
5. No NOAEL is available to 
finalise the evaluation of beta-ionone epoxide [FL-no: 07.170]. Flavouring Group Evaluation 82 Revision 1 
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In conclusion, the Panel considered that the substances [FL-no: 16.015, 16.018, 16.040 and 16.043] 
evaluated through the Procedure via the B-side of the Procedure scheme were of no safety concern at 
the estimated levels of intake based on the MSDI approach.  
CONCLUSION 
In Flavouring Group Evaluation 82, (FGE.82) the EFSA considered a group of epoxides evaluated by 
the JECFA at its 65
th meeting. 
The present revision is made due to inclusion of one additional substance, beta-ionone epoxide [FL-
no: 07.170], cleared for genotoxicity concern in FGE.210 Revision 1 and due to additional toxicity 
data have become available for beta-caryophyllene epoxide [FL-no: 16.043]. Since publication of 
FGE.82 the substance [FL-no: 16.051] is no longer supported by Industry for use as flavouring 
substance in Europe and will therefore not be considered any further.  
Therefore the present revision of FGE.82, FGE.82Rev1, considers five flavouring substances 
evaluated by the JECFA. 
The Panel does not agree with the application of the Procedure for the five epoxides as performed by 
JECFA. For the five substances [FL-no: 07.170, 16.015, 16.018, 16.040 and 16.043] it cannot be 
concluded that they are metabolised to innocuous substances and therefore their evaluation must 
proceed via the B-side of the Procedure scheme.  
A 90-day study on beta-caryophyllene epoxide has become available and a NOAEL of 109 mg/kg 
bw/day to provide adequate margin of safety is derived.  
The Panel considered that four of the five substances [FL-no: 16.043, 16.015, 16.018 and 16.040] 
evaluated through the Procedure via the B-side of the Procedure scheme were of no safety concern at 
the estimated levels of intake based on the MSDI approach. 
The evaluation of beta-ionone epoxide [FL-no: 07.170] cannot be finalised at step B4 of the procedure 
because a NOAEL from a 90-day study is not available. 
For the three substances [FL-no: 16.015, 16.018 and 16.040] evaluated through the Procedure use 
levels are needed to calculate the mTAMDIs in order to identify those flavouring substances that need 
more refined exposure assessment and to finalise their evaluation. 
In order to determine whether the conclusion for the five JECFA evaluated substances can be applied 
to the materials of commerce, it is necessary to consider the available specifications. Adequate 
specifications including complete purity criteria and identity tests are available for four JECFA 
evaluated substances [FL-no: 16.015, 16.018, 16.040 and 16.043]. For one substances [FL-no: 07.170] 
information on stereoisomeric composition is not adequate.  
Thus, for one substance evaluated through the Procedure [FL-no: 07.170] the Panel has reservations 
(data missing on stereoisomerism, need for additional toxicity data).  
For the remaining substances [FL-no: 16.015, 16.018, 16.040 and 16.043] the Panel agrees with the 
JECFA conclusion “No safety concern at estimated levels of intake as flavouring substances based on 
the MSDI approach. Flavouring Group Evaluation 82 Revision 1
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SUMMARY OF GENOTOXICITY DATA  
Table 4:   Summary of Genotoxicity Data (in vitro/in vivo) for Five Epoxides Evaluated by the JECFA (JECFA, 2006b) 
FL-no 
JECF
A-no 
EU Register name 
JECFA name 
Structural formula  End-point  Test system  Concentration  Results  Reference 
In vitro 
16.043 
1575 
beta-Caryophyllene epoxide 
O
 
Reverse mutation  S. typhimurium 
TA1535, TA1537 and 
TA1538  
0, 10, 100, 1,000, or 
10,000 µg/plate 
Negative
(a,b)  (Richold et al., 1979) 
Reverse mutation  S. typhimurium 
TA1535, TA1537,  
TA98 and TA100 
0, 10, 50, 100 or 500 
µg/plate 
Negative
(a,c)  (Richold et al., 1979) 
16.018 
1576 
Ethyl 3-phenyl-2,3-
epoxypropionate 
(=Ethyl 3-phenyllycidate, 
EPG) 
O
O
O  
Reverse mutation  S. typhimurium TA98, 
TA100, TA1535 and 
TA1537 
0, 10 to 500 µg/plate  Negative
(d,e)  (Canter et al., 1986) 
Reverse mutation  S. typhimurium TA98, 
TA100, TA1535 and 
TA1537 
0, 10 to 2,200 
µg/plate 
Negative
(f,g)  (Canter et al., 1986) 
Reverse mutation  S. typhimurium TA98, 
TA100,TA1535, 
TA1537 and TA1538 
0, 80, 400, or 2,000 
µg/plate 
Negative
(d,h) 
 
(Tilch and Elias, 1984) 
Negative / 
Positive
(f,i) 
Reverse mutation  S. typhimurium TA98, 
TA100,TA1535, 
TA1537 and TA1538 
0, 400, 2,000, or 
10,000 µg/plate
(j) 
Negative
(a)  (Tilch and Elias, 1984) 
Reverse mutation  S. typhimurium TA100  0, 200, 500, 1,000, or 
2,000µg/mL 
Negative 
/Positive
(a,k) 
(Voogd et al., 1981) 
Reverse mutation  S. typhimurium TA100 
and TA98 
0, 25, 50, 100, 250, 
500, 1,000, 2,500, or 
5,000 µg/plate 
Negative 
/Positive
(d,i) 
(Wagner and Walton, 
1999) 
Positive
(f) 
Reverse mutation  S. typhimurium 
TA1535, TA1537, 
TA1538, TA98 and 
TA100 
Up to 4,000 µg/plate  Negative 
/Positive
(a,i) 
(Wild et al., 1983) 
SOS chromotest  Escherichia coli PQ37  0, 0.01, 0.03, 0.1, 0.3, 
or 1.0 mmol/L (0, 
1.9, 5.8, 19.2, 57.7, or 
Negative
(a)  (von der Hude et al., 
1990a) Flavouring Group Evaluation 82 Revision 1
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Table 4:   Summary of Genotoxicity Data (in vitro/in vivo) for Five Epoxides Evaluated by the JECFA (JECFA, 2006b) 
192.2 µg/mL) 
Sister chromatid 
exchange 
Chinese hamster ovary-
K1-BH4 cells 
0 or 103 µg/mL 
(0.103 mg/mL) 
Positive
(a)  (Tilch and Elias, 1984) 
Sister chromatid 
exchange 
Chinese hamster ovary-
K1-BH4 cells 
0 or 3,280 µg/mL 
(3.28 mg/mL) 
Negative
(a)  (Tilch and Elias, 1984) 
Sister chromatid 
exchange 
Chinese hamster V79 
cells 
0, 0.078, 0.16, 0.32, 
0.63, 1.25, or 2.5 
mmol/L (0, 15, 30.8, 
61.5, 121.1, 240.3, or 
480.5 µg/mL) 
Positive
(l,m)  (von der Hude et al., 
1991) 
16.015 
1577 
Ethyl 
methylphenylglycidate 
O
O
O  
Reverse mutation  S. typhimurium TA98, 
TA100, TA1535 and 
TA1537 
0, 100 to 10,000 
µg/plate 
Negative
(a,n)  (Canter et al., 1986) 
Reverse mutation  S. typhimurium TA100  0, 200, 500, 1,000, 
2,000, or 5,000 
µg/mL 
Negative
(a)  (Voogd et al., 1981) 
Reverse mutation  S. typhimurium 
TA1535, TA1537, 
TA1538, TA98 and 
TA100 
Up to 3,600 µg/plate  Negative
(a)  (Wild et al., 1983) 
Reverse mutation  S. typhimurium 
TA1535, TA1537, 
TA1538, TA98 and 
TA100 
Up to 1,200 µg/plate  Negative
(a,o)  (Wild et al., 1983) 
Sister chromatid 
exchange 
Chinese hamster ovary 
cells W B1 
 0, 16, 50, or 160 
μg/mL 
Positive
(d)  (Galloway et al., 1987) 
0, 16, 50, 160, or 500 
μg/mL 
Negative
(f) 
Chromosomal 
aberration 
Chinese hamster ovary 
cells W B1 
 0, 50, 160, or 500 
μg/mL 
Positive
(d)  (Galloway et al., 1987)
Equivocal
(f,p) 
In vivo 
16.018 
1576 
Ethyl 3-phenyl-2,3-
epoxypropionate 
O
O
O  
Sex-linked 
recessive lethal 
mutation (Basc 
test) 
Drosophila 
melanogaster 
0 or 2.5 mM (480.5 
µg/mL) 
Negative
(q)  (Wild et al., 1983) 
Micronucleus 
induction 
NMRI Mice  0, 577, 961, or 1,538 
mg/kg
(r) 
Negative  (Wild et al., 1983) 
16.015 Ethyl 
O
O Sex-linked  Drosophila  0 or 10 mM (2,062.4  Weakly  (Wild et al., 1983) Flavouring Group Evaluation 82 Revision 1
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Table 4:   Summary of Genotoxicity Data (in vitro/in vivo) for Five Epoxides Evaluated by the JECFA (JECFA, 2006b) 
1577 methylphenylglycidate  recessive  lethal 
mutation (Basc 
test) 
melanogaster  µg/mL)
(s) Positive 
Micronucleus 
induction 
NMRI Mice  0, 619, 1,237, or 
1,856 mg/kg
(r) 
Negative  (Wild et al., 1983) 
(a):  With or without S9 activation. 
(b):  Cytotoxicity was observed at concentrations of 1,000 µg/plate and 10,000 µg/plate in S. typhimurium strains TA1535, TA1537 and TA1538. 
(c):  Cytotoxicity was observed at 500 µg/plate in S. typhimurium strains TA100 and TA98. Results for strain TA1538 were not reported with metabolic activation due to sample contamination. 
(d): Without  S9  activation. 
(e):  Cytotoxicity was observed at the highest dose in all strains tested. 
(f):  With S9 activation. 
(g):  Cytotoxicity was observed at concentrations of 1,600 and 2,200 µg/plate in all strains tested. 
(h): Cytotoxicity  was  observed at 2,000 µg/plate in S. typhimurium strains TA98, TA1535 and TA1538. 
(i): Only  S. typhimurium strain TA100 showed mutagenic activity.  Negative in all other strains of S. typhimurium tested. 
(j):  An in vitro pepsin and pancreatin digest of ethyl 3-phenylglycidate; performed in order to simulate mammalian digestion. 
(k):  Positive only at the 2 highest concentrations tested (i.e., 1,000 and 2,000 µg/mL). 
(l):  Precipitation and cytotoxicity reported at 2.5 mmol/L (480.5 µg/mL). 
(m): Absence or presence of metabolic activation not specified. 
(n):  Cytotoxicity was observed at 10,000 µg/plate in S. typhimurium strain TA100. 
(o): Pre-incubation  method. 
(p):  For equivocal results, the P value was reported as <0.003 using the trend test; however, none of the doses were significant at P ≤0.05 using the Dunnett method. 
(q):  Statistically significant increase in the number of SLRL mutations in only 1 out of 3 experiments and only in the 1st of 3 broods.  Moreover, the cumulative number of SLRL mutations 
obtained in all 3 experiments for the 1st brood was not statistically different in comparison to controls. 
(r): Single  intraperitoneal  doses. 
(s):  Statistically significant increase in the number of SLRL mutations in only 1 out of 4 experiments and only in the 1st of 3 broods; however, the cumulative number of SLRL mutations 
obtained in all 4 experiments for the 1st brood also was significantly increased in comparison to controls. Flavouring Group Evaluation 82 Revision 1
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Table 5:   Genotoxicity Data (in vitro) EFSA / FGE.210Rev1 
Chemical Name 
FL-no 
Test System 
in vitro  
Test Object   Concentrations of Substance 
and Test Conditions  
Result   Reference   Comments  
beta-Ionone 
epoxide 07.170 
Reverse 
Mutation 
S. typhimurium TA98, 
TA100, TA1535, and 
TA1537 
5 - 500 μg/plate 
(d,c)  Negative (Jones  and 
Wilson, 1988) 
No statistically significant increase in revertant 
numbers was seen at any concentration, either in 
the presence or absence of S9-mix. 
S. typhimurium TA97a, 
TA98, TA100, TA1535 
501, 1582 and 5000 μg/plate 
(a,c)
 
158, 501 and 1582 μg/plate 
(b,c) 
 
 
 
 
 
Negative 
 
Negative 
 
(Kringstad, 2005)  Evidence of toxicity was observed at the highest 
concentration in strain TA97a in the absence of 
S9-mix and in TA100 in the absence and 
presence of S9-mix. The study therefore complies 
with current recommendations for upper 
concentration limit inclusion. The study included 
3 replicate plates per concentration, and was GLP 
compliant. 
E. coli WP2uvrA  501, 1582 and 5000 μg/plate 
(a,c) 
158, 501 and 1582 μg/plate 
(b,c) 
Negative 
Negative  
 
tk Mutation 
Induction 
Mouse Lymphoma 
L5178Y T/K +/- 3.7.2c 
cells 
200 - 900 μg/mL 
(d,e)  
4.1 - 520 μg/mL 
(a,f) 
Negative 
Negative 
(Flanders, 2006)  A preliminary range-finder assay was conducted 
to establish maximum concentrations. Top 
concentrations in each arm of the study induced 
77, 85, and 80 % reductions in relative total 
growth. The study therefore complies with 
current recommendations. 
(a): Without  S9  metabolic  activation. 
(b):  With S9 metabolic activation. 
(c): Plate  incorporation  method. 
(d):  With and without S9 metabolic activation. 
(e): 4-hour  treatment. 
(f): 24-hour  treatment. Flavouring Group Evaluation 82 Revision 1
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SUMMARY OF SAFETY EVALUATIONS 
Table 6:   Summary of Safety Evaluation by the JECFA (JECFA, 2006b) 
FL-no 
JECFA-no 
EU Register name  Structural formula  EU MSDI 
(a)  
US MSDI 
(μg/capita/day) 
Class 
(b) 
Evaluation procedure 
path 
(c) 
Outcome on 
the named 
compound [
(d) 
or 
(e)] 
EFSA conclusion on 
the named compound 
(Procedure steps, 
intake estimates, 
NOAEL, 
genotoxicity) 
EFSA conclusion on 
the material of 
commerce 
07.170 
1571 
beta-Ionone epoxide 
O
O 0.073 
0.1 
Class III 
A3: Intake below 
threshold 
d    
16.040 
1578 
Ethyl 2,3-epoxy-3-
methyl-3-p-
tolylpropionate 
O
O
O  
20 
0.009 
Class III 
A3: Intake below 
threshold 
d  No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
16.043 
1575 
beta-Caryophyllene 
epoxide 
O
 
8 
0.1 
Class III 
A3: Intake below 
threshold 
d  No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
Register name to be 
changed to 
1R,4R,6R,10S-beta-
caryophyllene epoxide. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
16.051 
1573 
Epoxy oxophorone 
O
O
O
0.012 
0.2 
Class III 
A3: Intake below 
threshold 
d Genotoxicity  data 
required. 
No longer supported 
by Industry, (DG 
SANCO, 2012). 
16.015 
1577 
Ethyl 
methylphenylglycidate 
O
O
O  
205 
1840 
Class III 
A3: Intake above 
threshold, A4: Not 
endogenous, A5: 
Adequate NOAEL exists 
d  No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
16.018 
1576 
Ethyl 3-phenyl-2,3-
epoxypropionate 
O
O
O  
97 
96 
Class III 
A3: Intake above 
threshold, A4: Not 
endogenous, A5: 
Adequate NOAEL exists 
d  No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. 
No safety concern at 
the estimated level of 
intake based on the 
MSDI approach. Flavouring Group Evaluation 82 Revision 1
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(a):  EU MSDI: Amount added to food as flavour in (kg / year) x 10E9 / (0.1 x population in Europe (= 375 x 10E6) x 0.6 x 365)  =  µg/capita/day. 
(b):  Thresholds of concern: Class I = 1800 µg/person/day, Class II = 540 µg/person/day, Class III = 90 µg/person/day. 
(c):  Procedure path A substances can be predicted to be metabolised to innocuous products.  Procedure path B substances cannot. 
(d):  No safety concern based on intake calculated by the MSDI approach of the named compound. 
(e):  Data must be available on the substance or closely related substances to perform a safety evaluation. 
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ABBREVIATIONS 
BW   Body  Weight 
CAS    Chemical Abstract Service 
CEF    Panel on Food Contact Materials, Enzymes, Flavourings and Processing Aids 
CHO    Chinese hamster ovary (cells) 
CoE   Council  of  Europe 
DNA   Deoxyribonucleic  acid 
EFFA    European Flavour and Fragrance Association 
EFSA    The European Food Safety Authority 
EPA    United States Environmental Protection Agency  
EU   European  Union 
FAO    Food and Agriculture Organization of the United Nations  
FEMA    Flavor and Extract Manufacturers Association 
FGE    Flavouring Group Evaluation  
FLAVIS (FL)  Flavour Information System (database) 
GLP    Good laboratory practice 
HPRT   Hypoxanthine  Phosphoribosyl  transferase 
ID   Identity 
IP   Intraperitoneal 
IR   Infrared  spectroscopy 
JECFA   The Joint FAO/WHO Expert Committee on Food Additives 
MNBN   Micronucleated Binucleate cells 
MSDI    Maximised Survey-derived Daily Intake 
mTAMDI  Modified Theoretical Added Maximum Daily Intake 
NCE   Normochromatic  erythrocyte 
No   Number 
NOAEL  No Observed Adverse Effect Level 
NTP    National Toxicology Program Flavouring Group Evaluation 82 Revision 1 
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OECD    Organization for Economic Cooperation and Development  
PCE   Polychromatic  erythrocyte 
RI   Replication  Index 
SCE    Sister chromatic exchange 
SCF    Scientific Committee on Food 
UDS    Unscheduled DNA Synthesis 
WHO   World  Health  Organisation 